Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated certain GI diseases. Source
No articles found.
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
St. Renatus, LLC, named after the patron saint of anesthesia, is a privately held ...
St. Renatus, LLC, named after the patron saint ...
Neuronetics, Inc. is focused on designing, developing, and marketing products that...
Neuronetics, Inc. is focused on designing, deve...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Liquidia is a late-stage clinical biopharmaceutical company focused on the develop...
Liquidia is a late-stage clinical biopharmaceut...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Join the National Investor Network and get the latest information with your interests in mind.